KLF6 and Cirrhosis: Furthermore, KLF6 is upregulated during liver fibrosis, which was confirmed in an animal model of liver cirrhosis and human liver cirrhosis (Bureau et al., 2008; Vatakuti et al., 2015), and targeted KLF6 therapy has been demonstrated to inhibit advanced liver fibrosis and attenuates angioarchitectural changes that typify cirrhosis (Thabut et al., 2011).